Treatments for Alpha-1 Proteinase Inhibitor Deficiency

 Treatments for Alpha-1 Proteinase Inhibitor Deficiency

Drugs used to treat Alpha-1 Proteinase Inhibitor Deficiency

 

Aralast NP

Glassia

Aralast

alpha 1-proteinase inhibitor

Zemaira

Prolastin-C

 

What is Alpha-1 Proteinase Inhibitor Deficiency?

 

Alpha-1 Proteinase Inhibitor Deficiency (Alpha-1 Antitrypsin Deficiency or AATD) is a hereditary disorder that results from a deficiency in the protein called alpha-1 antitrypsin (AAT), also known as alpha-1 proteinase inhibitor. AAT is produced mainly in the liver and released into the bloodstream, where it helps protect tissues in the lungs and other organs from damage caused by enzymes, particularly neutrophil elastase, which is released by immune cells in response to infection or inflammation.

 

When there is a deficiency or dysfunction of AAT, enzymes like neutrophil elastase are not adequately inhibited. This can lead to a breakdown of lung tissue, resulting in chronic obstructive pulmonary disease (COPD), emphysema, or chronic bronchitis. AAT deficiency can also cause liver disease due to the accumulation of abnormal AAT proteins in the liver, leading to cirrhosis or liver failure.

 

Causes

AATD is an autosomal recessive genetic disorder, meaning that a person must inherit two defective genes (one from each parent) to develop the condition. The SERPINA1 gene on chromosome 14 is responsible for producing AAT. Different mutations in this gene result in different levels of AAT in the blood. The most common alleles (variants) of the SERPINA1 gene are:

- M allele: Normal AAT production.

- S allele: Moderately reduced AAT production.

- Z allele: Severely reduced AAT production. The ZZ genotype is the most common and severe form associated with AATD.

 

People with an MZ or SZ genotype may have an intermediate risk of developing lung disease, while individuals with **ZZ genotype** have a high risk for both lung and liver disease.

 

Symptoms

The symptoms of AATD vary depending on the severity of the deficiency, the organs involved, and the patient’s exposure to lung irritants (e.g., smoking, pollution). Common symptoms include:

 

Respiratory Symptoms

- Shortness of breath

- Chronic cough and sputum production

- Wheezing or asthma-like symptoms

- Frequent lung infections and pneumonia

- Early onset of **emphysema or COPD** (often between ages 20 and 50)

 

Liver Symptoms

- Elevated liver enzymes detectable in blood tests

- Jaundice (yellowing of the skin and eyes)

- Swelling in the abdomen (due to liver dysfunction and fluid retention)

- Cirrhosis or scarring of the liver, which may lead to liver failure

- Hepatocellular carcinoma (increased risk of liver cancer)

 

Diagnosis

AATD is often underdiagnosed or misdiagnosed because its symptoms are similar to those of other respiratory and liver diseases. Diagnosis typically involves:

 

1. Blood Test: To measure the levels of AAT in the blood. Low levels suggest a deficiency.

2. Genetic Testing: To identify the specific alleles and confirm the diagnosis.

3. Liver Function Tests: To assess liver health and identify any abnormalities.

4. Pulmonary Function Tests (PFTs): To assess lung function and determine the presence and extent of lung disease.

5. Imaging Studies: Chest X-rays and CT scans to check for emphysema or other lung damage.

 

Treatment and Management

While there is no cure for AATD, treatment focuses on managing symptoms, slowing disease progression, and improving quality of life:

 

1. Augmentation Therapy: Intravenous infusions of purified AAT protein to increase the levels in the blood, helping to protect lung tissue. This therapy is used primarily for patients with lung involvement.

2. Lifestyle Modifications:

   - Smoking cessation (crucial as smoking accelerates lung damage in AATD patients).

   - Avoidance of lung irritants and infections.

3. Medications:

   - Bronchodilators and **inhaled corticosteroids** to reduce lung inflammation.

   - Antibiotics to treat respiratory infections.

4. Vaccinations: Pneumococcal and influenza vaccinations to reduce the risk of lung infections.

5. Liver Transplant: In cases of advanced liver disease, a liver transplant may be required, as it provides a new source of normal AAT production.

6. Lung Transplant: For severe, end-stage lung disease.

 

Prognosis

The prognosis of AATD varies. Some people remain asymptomatic, while others may develop severe lung and/or liver disease. Lifelong monitoring, lifestyle adjustments, and early intervention can significantly impact life expectancy and quality of life. Early diagnosis and appropriate management can help prevent or delay the progression of disease, particularly lung disease.

 

Prevalence and Genetic Screening

AATD is estimated to affect approximately 1 in 3,500 to 5,000 people worldwide, with higher prevalence among people of European descent. Family members of affected individuals are encouraged to undergo genetic screening, particularly if they exhibit symptoms of lung or liver disease.